Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth
BCL-2 inhibitor
Merkel cell carcinoma
Merkel cell polyomavirus
PI3K inhibitor
apoptosis
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
07
2020
accepted:
29
10
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
7
1
2021
Statut:
epublish
Résumé
Merkel cell carcinoma (MCC) is a highly malignant skin cancer. Despite major treatment improvements during the last decade, up to 50% of patients do not respond to therapy or develop recurrent disease. For these patients, alternative treatment options are urgently needed. Here, we assessed the efficacy of the combination of the BCL-2 inhibitor Navitoclax and the PI3K p110α inhibitor Alpelisib in MCC cell lines. The expression of BCL-2 was assessed by immunohistochemistry in MCC and MCC cell lines. Treatment with Navitoclax and Alpelisib alone and in combination was performed on four MCC cell lines. The decrease of cell viability during treatment was assessed by XTT assay and visualized for the combinations by 3D combinatorial index plotting. The increase of apoptotic cells was determined by cleaved PARP Western blotting and Annexin V staining. Some 94% of MCCs and all three MCPyV-positive cell lines showed BCL-2 expression. Navitoclax monotreatment was shown to be highly effective when treating BCL-2-positive cell lines (IC Our results show that the anti-apoptotic BCL-2 is frequently expressed in MCC and MCC cell lines. Inhibition of BCL-2 by Navitoclax in combination with Alpelisib revealed a strong synergy and prolonged inhibition of MCC cell viability and induction of apoptosis. The combination of Navitoclax and Alpelisib is a novel potential treatment option for MCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Merkel cell carcinoma (MCC) is a highly malignant skin cancer. Despite major treatment improvements during the last decade, up to 50% of patients do not respond to therapy or develop recurrent disease. For these patients, alternative treatment options are urgently needed. Here, we assessed the efficacy of the combination of the BCL-2 inhibitor Navitoclax and the PI3K p110α inhibitor Alpelisib in MCC cell lines.
METHODS
METHODS
The expression of BCL-2 was assessed by immunohistochemistry in MCC and MCC cell lines. Treatment with Navitoclax and Alpelisib alone and in combination was performed on four MCC cell lines. The decrease of cell viability during treatment was assessed by XTT assay and visualized for the combinations by 3D combinatorial index plotting. The increase of apoptotic cells was determined by cleaved PARP Western blotting and Annexin V staining.
RESULTS
RESULTS
Some 94% of MCCs and all three MCPyV-positive cell lines showed BCL-2 expression. Navitoclax monotreatment was shown to be highly effective when treating BCL-2-positive cell lines (IC
DISCUSSION
CONCLUSIONS
Our results show that the anti-apoptotic BCL-2 is frequently expressed in MCC and MCC cell lines. Inhibition of BCL-2 by Navitoclax in combination with Alpelisib revealed a strong synergy and prolonged inhibition of MCC cell viability and induction of apoptosis. The combination of Navitoclax and Alpelisib is a novel potential treatment option for MCC patients.
Identifiants
pubmed: 33403016
doi: 10.1177/1758835920975621
pii: 10.1177_1758835920975621
pmc: PMC7739210
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920975621Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interest: The authors declare that there is no conflict of interest.
Références
Clin Cancer Res. 2014 Apr 1;20(7):1768-78
pubmed: 24526738
Dermatol Ther (Heidelb). 2019 Jun;9(2):209-222
pubmed: 30820877
Hum Pathol. 2015 Sep;46(9):1290-6
pubmed: 26099430
Mod Pathol. 2007 Nov;20(11):1113-20
pubmed: 17885674
Cytokine. 2017 Oct;98:33-41
pubmed: 28277287
Clin Cancer Res. 2012 Mar 1;18(5):1227-36
pubmed: 22261808
J Clin Oncol. 2012 Feb 10;30(5):488-96
pubmed: 22184378
J Invest Dermatol. 2014 Aug;134(8):2241-2250
pubmed: 24614157
Cell Death Dis. 2019 Apr 24;10(5):342
pubmed: 31019203
Cancer Immunol Res. 2013 Jul;1(1):54-63
pubmed: 24416729
Ann Pharmacother. 2018 Sep;52(9):928-935
pubmed: 29616562
Eur J Cancer. 2017 Jan;71:53-69
pubmed: 27984768
Int J Mol Sci. 2018 Dec 08;19(12):
pubmed: 30544835
Cancer Res. 2013 Aug 15;73(16):4982-7
pubmed: 23576560
Mol Cancer Res. 2014 Jul;12(7):987-1001
pubmed: 24757258
Clin Cancer Res. 2012 Jun 1;18(11):3163-9
pubmed: 22496272
Lancet Oncol. 2010 Dec;11(12):1149-59
pubmed: 21094089
Am J Dermatopathol. 1996 Jun;18(3):273-7
pubmed: 8806961
Virchows Arch. 2012 Nov;461(5):553-9
pubmed: 22976527
Cancer Med. 2016 Sep;5(9):2294-301
pubmed: 27431483
J BUON. 2019 Sep-Oct;24(5):2155-2160
pubmed: 31786889
Exp Dermatol. 1996 Apr;5(2):102-7
pubmed: 8734919
J Clin Oncol. 2011 Mar 1;29(7):909-16
pubmed: 21282543
Nat Rev Dis Primers. 2017 Oct 26;3:17077
pubmed: 29072302
Cancer Res. 2018 Jun 1;78(11):3075-3086
pubmed: 29559471
Cancer Res. 2015 Sep 15;75(18):3720-3727
pubmed: 26238782
Br J Haematol. 2015 Sep;170(5):669-78
pubmed: 25942994
Curr Opin Oncol. 2019 Mar;31(2):72-83
pubmed: 30694842
Brief Funct Genomic Proteomic. 2008 Jan;7(1):27-34
pubmed: 18283052
Drugs. 2019 Jul;79(11):1249-1253
pubmed: 31256368
JCI Insight. 2019 Mar 12;5:
pubmed: 30860495
Oncotarget. 2018 Jul 3;9(51):29565-29573
pubmed: 30038704
Mol Cancer Ther. 2016 Jun;15(6):1248-60
pubmed: 27197306
PLoS One. 2012;7(2):e31255
pubmed: 22363598
Cancer Res. 2013 Feb 15;73(4):1340-51
pubmed: 23243017
Am J Dermatopathol. 2012 Aug;34(6):592-6
pubmed: 22814318
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
J Immunol Methods. 1995 Jul 17;184(1):39-51
pubmed: 7622868
J Clin Oncol. 2018 May 1;36(13):1291-1299
pubmed: 29401002
Blood. 2006 Feb 15;107(4):1570-81
pubmed: 16249385
Leuk Lymphoma. 2015;56(10):2826-33
pubmed: 25797560
Nat Rev Clin Oncol. 2018 Dec;15(12):763-776
pubmed: 30287935
Oncogene. 2019 Jan;38(1):47-59
pubmed: 30076411
Clin Cancer Res. 2013 Oct 1;19(19):5351-60
pubmed: 23922299
Cancer Chemother Pharmacol. 2014 Sep;74(3):593-602
pubmed: 25053389
Oncotarget. 2017 Jul 13;8(45):79731-79741
pubmed: 29108353
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Curr Opin Oncol. 2020 Mar;32(2):114-121
pubmed: 31972727
Hum Pathol. 1999 Nov;30(11):1367-72
pubmed: 10571519
Hum Pathol. 2016 Oct;56:128-33
pubmed: 27343835